Arbutus Biopharma (ABUS) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 79.6% versus a loss of 4.3%. Over five years, ABUS leads with a +4.7% price change compared with -30.2% for DSGN. Arbutus Biopharma is the larger company by market cap ($646.8 million vs $645.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | DSGN |
|---|---|---|
| Share price | $4.22 | $10.31 |
| Market cap | $646.82M | $645.22M |
| 1-day change | -1.63% | -1.62% |
| YTD return | -12.27% | +9.91% |
| 1-year return | -4.31% | +79.62% |
| 5-year return | +4.71% | -30.20% |
| P/E ratio (TTM) | 5.34 | — |
| EPS (TTM) | $0.79 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | $0 |
| Revenue growth (YoY) | +128.21% | — |
| Net income (latest FY) | $-33.50M | $-69.79M |
| Operating margin | -270.96% | — |
| Net margin | -237.88% | — |
| 52-week high | $5.45 | $17.25 |
| 52-week low | $3.50 | $5.28 |
| Distance from 52-week high | -22.57% | -40.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +27.96% | +110.57% |
| Average volume | 4.81M | 603.35K |
| Shares outstanding | 153.28M | 62.58M |
| Employees | 19 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed ABUS by 83.9 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
ABUS vs DSGN FAQ
Which is bigger, Arbutus Biopharma or Design Therapeutics?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $646.82M compared with $645.22M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, ABUS or DSGN?
DSGN returned +79.62% over the past 12 months, compared with -4.31% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.